Clinical trial
Study of Omalizumab in Moderate to Severe Bronchial Asthma
NCT00232050 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00232050 |
|---|---|
| Title | Study of Omalizumab in Moderate to Severe Bronchial Asthma |
| Official title | Study of Omalizumab in Moderate to Severe Bronchial Asthma |
| Lead sponsor | Novartis, Industry |
| Collaborators | Daiichi Sankyo Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab |
| Enrollment | 327 |
| Start date | Oct 1, 2002 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Oct 4, 2005 |
| Last update posted | Oct 25, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: